Navigation Links
Lombardi research: Robotic radiosurgery offers palliative care for hilar lung tumors

Washington, DC Patients report decreased pain and improved breathing following treatment of their hilar tumors with robotic radiosurgery, but researchers say the therapy falls short of improving survival. Still, the study, conducted by researchers at Georgetown Lombardi Comprehensive Cancer Center and presented today at the annual meeting of the American College of Chest Physicians in Vancouver, BC, represents the first of its kind to document the use of radiosurgery for hilar tumors and presents a novel therapy option.

For the study, researchers reviewed the medical records of patients diagnosed with inoperable primary and metastatic hilar lung tumors. Hilar tumors abut or invade the mainstem bronchus. All the patients in the study were treated with five courses (30 to 40 Gy in 5 fractions) of radiotherapy using CyberKnife. Imaging studies with a combined PET/CT scan were performed at three and six-month follow-up intervals to track tumor progression.

The record review included 24 patients -- four with inoperable primary hilar lung tumors and 20 with hilar tumors that had spread there from other primary sites. The mean radiation dose administered to the esophagus was 27 Gy (ranging from 11 to 40 Gy) and mean radiation dose administered to the lung was 45 Gy (ranging from 30 to 50 GY).

At one-year, the overall survival was 61 percent and local control (ability to keep the tumor from growing) was 71 percent.The review found that most deaths were attributed to the spread of the patients' cancers. However, there was one death that was attributed to an opening in the mainstem bronchus in a patient who was previously stented.

While no uniform data was collected from patients about quality of life at the time of their treatment, the study's lead author says the patient records reflect comments made by patients about their symptoms.

"Patients reported improvement with coughing, breathing, and they reported less pain," said Brian Collins, MD, a radiation oncologist with Lombardi and lead author of the study.

"Our study suggests that CyberKnife is a palliative treatment option for hilar lung tumors," explains Collins. "We'd like to investigate outcomes with increased radiation doses to see if we can improve local control and overall survival rates. And we'd like to study the impact of administering a drug to make the tumors more sensitive to radiation.

"This is an important first step that gives us a new option to treat potentially morbid hilar tumor," Collins concludes. "Future studies would likely involve drugs to make the tumor more sensitive to radiation."


Contact: Karen Mallet
Georgetown University Medical Center

Related medicine news :

1. Susan G. Komen for the Cure awards grant to Lombardis V. Craig Jordan
2. Lombardi research teams hone in on treatments for osteosarcoma and Ewings sarcoma
3. GUMCs Lombardi Hosts Symposium Exploring Future of Cancer Research and Personalized Medicine
4. Most Americans Back Embryonic Stem Cell Research: Poll
5. Womens health research: IOM releases progress report Sept. 23
6. Health care research: $1.6 million in new funding for University of Montreal
7. Research: Schwartz Center Rounds encourage compassionate health care and better teamwork
8. Implementing comparative effectiveness research: Lessons from the mammography screening controversy
9. Research: Major breakthrough will revolutionize the screening and treatment of genetic diseases
10. National Event Addresses Breakthroughs in Crohn's & Colitis Research: National Expert & Researcher Answers Key Questions on Interactive Webcast/Teleconference
11. Research: How you think about your age may affect how you age
Post Your Comments:
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: